Glaukos (GKOS) reported $507M in revenue for fiscal 2025, +32.3% year on year. That ranks #2196 by revenue among 2853 SEC filers and #214 in Healthcare. It posted a net loss of −$188M for the same year. Revenue has grown 18.0% a year on average since 2016 ($114M then). The fiscal 2025 balance sheet shows $893M in total assets, $90.8M in cash and $765,000 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $507M | +32.3% | FY20252025-12-31 |
| Gross profitGrossProfit | $283M | −2.3% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$200M | −$77.2M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$188M | −$41.3M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$14.8M | +$46.5M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $7.7M | +21.7% | FY20252025-12-31 |
| Total assetsAssets | $893M | −8.3% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $656M | −14.4% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $90.8M | −46.5% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $765,000 | −91.5% | FY20152015-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $151M | −$19.8M | Open → |
| Q2 20262026-06-30 | $186M | −$18.4M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Glaukos Corp
- Ticker
- GKOS
- Exchange
- NYSE
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0001192448
Filings
- 10-QJul 29, 2026Open filing →
- 10-QApr 30, 2026Open filing →
- 10-KFeb 23, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| VeracyteVCYT | $517M | $66.4M |
| InotivNOTVQ | $513M | −$68.6M |
| Adma BiologicsADMA | $510M | $147M |
| GlaukosGKOS | $507M | −$188M |
| Starling OncologySTLN | $503M | $60.6M |
| Bridgebio PharmaBBIO | $502M | −$733M |
| Ascend WellnessAAWH | $501M | −$118M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Glaukos — Key figures |url=https://companiesranked.com/en/company/glaukos |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Glaukos — Key figures. CompaniesRanked. https://companiesranked.com/en/company/glaukosBibTeX
@misc{companiesranked-en-company-glaukos-2026,
author = {{CompaniesRanked}},
title = {{Glaukos — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/glaukos}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-061944 · February 23, 2026
{{cite web |title=Glaukos — Key figures — 10-K (0001193125-26-061944) |url=https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/gkos-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-23}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.